PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA ...

DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...

DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

GE Healthcare’s DaTscan has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB). This new indication is in addition to its ...

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscan™ (Ioflupane I 123 injection), with ...

GE Healthcare today presented the results of a randomized study analyzing the effect of DaTSCAN TM (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with a diagnosis of possible ...

GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN TM (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with Clinically ...